Efficacy News and Research

RSS

Combination drug therapy cures chronic hepatitis C in co-infected HIV patients

A multicenter team of researchers report that in a phase III clinical trial, a combination drug therapy cures chronic hepatitis C in the majority of patients co-infected with both HIV and hepatitis C.

21 Jul 2014

13 researchers awarded National Psoriasis Foundation fellowship to study psoriasis

Twelve residents and medical students each received a one-year, $50,000 National Psoriasis Foundation fellowship to study psoriasis. The fellowships aim to increase the number of scientists studying and treating psoriatic disease by encouraging promising doctors to dedicate their careers to the study of psoriasis as physician researchers.

18 Jul 2014

FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

The U.S. Food and Drug Administration yesterday approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).

18 Jul 2014

Gene therapy offers potential alternative to pacemakers

Researchers have developed a gene transplant procedure that can transform ordinary heart muscle cells into “biological pacemaker” cells that maintain heart rhythm.

17 Jul 2014

Ruthigen treats first human subjects with leading drug candidate RUT58-60

Ruthigen, Inc., today announced that it has treated the first human subjects with its leading drug candidate RUT58-60 in a 30 patient, 21-day skin irritation trial, which is expected to be completed in August 2014.

17 Jul 2014

PharmaBoardroom's "Healthcare and Life Sciences Review Poland 2014" report

PharmaBoardroom's "Healthcare and Life Sciences Review Poland 2014", is now available for free download. The report explores one of Europe's largest pharma markets, and looks at the delicate balance between a strong and growing economy, and healthcare legislation that many complain is negatively affecting the pharmaceutical market.

17 Jul 2014

Phase 2 dose-ranging study of AYX1 for prevention of post-surgical pain

Adynxx, developer of a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in ADYX-003, a Phase 2 dose-ranging study of AYX1, an investigational drug candidate for the prevention of post-surgical pain.

17 Jul 2014

MPP announces 7 new sub-licensing agreements for manufacture of generic HIV medicines

MPP forges first agreement with a Chinese manufacturer Desano; and with Cipla, Mylan and Micro Labs; Extends Collaborations with Aurobindo, Laurus Labs and Emcure

17 Jul 2014

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation to nintedanib, an investigational therapy currently under FDA review for the treatment of people with idiopathic pulmonary fibrosis (IPF).

17 Jul 2014

Once-a-day pill for patients experiencing opioid-induced constipation

Opioids - strong morphine-based painkillers - are widely prescribed to patients experiencing chronic severe pain. While these drugs are very effective for treating and managing pain, they have one particularly bothersome side effect: constipation.

17 Jul 2014

Phase III research shows that new drug improves symptoms related to plaque psoriasis

Randomized, phase III research from the University of Alabama at Birmingham shows that a new drug improves symptoms related to moderate to severe plaque psoriasis, a chronic skin disease of scaling and inflammation.

17 Jul 2014

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel Pharmaceuticals, Inc. today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura).

16 Jul 2014

GrowBLOX enters Florida Medical Marijuana Market through new subsidiary, GB Sciences

GrowBLOX Sciences, Inc. a medical marijuana research and development company, is pleased to announce it has entered the Florida Medical Marijuana Market through its new subsidiary, GB Sciences Florida, LLC. With nearly 20 million residents, Florida is poised to be the biggest medical marijuana market outside of California.

16 Jul 2014

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

The basic idea of cancer chemoprevention is to arrest or reverse the progression of premalignant cells towards full malignancy, using physiological mechanisms that do not kill healthy cells.

16 Jul 2014

Citalopram can increase efficacy of BMSCs differentiating into neuronal-like cells

There is evidence that selective serotonin reuptake inhibitor antidepressants can promote neuronal cell proliferation and enhance neuroplasticity both in vitro and in vivo.

16 Jul 2014

OSU creates new assay to test authenticity of primary drugs used to treat malaria

Chemists and students in science and engineering at Oregon State University have created a new type of chemical test, or assay, that's inexpensive, simple, and can tell whether or not one of the primary drugs being used to treat malaria is genuine - an enormous and deadly problem in the developing world.

16 Jul 2014

Hydroxychloroquine treatment not effective for primary Sjögren syndrome

Among patients with the systemic autoimmune disease primary Sjögren syndrome, use of hydroxychloroquine, the most frequently prescribed treatment for the disorder, did not improve symptoms during 24 weeks of treatment compared with placebo, according to a study in the July 16 issue of JAMA.

16 Jul 2014

Healthy lifestyle helps hard-to-treat hypertensive patients

Maintaining a healthy lifestyle can prevent cardiovascular events even among patients with apparent treatment-resistant hypertension, say researchers.

15 Jul 2014

Pfizer to in-license Absorption Systems' BCRP-MDCK cells

Absorption Systems, a leader in novel test systems for drug transporters, announces a license agreement with Pfizer Inc., in which Pfizer will in-license Absorption Systems' BCRP-MDCK cells. This cell line is stably transfected with the human ABCG2 gene, which codes for a protein known as BCRP (breast cancer resistance protein).

15 Jul 2014

Paracetamol safety and osteoarthritis: an interview with Professor David Hunter, University of Sydney

Firstly, paracetamol has been the first-line recommended treatment for osteoarthritis pain for very many years and, secondly, it is readily available over the counter and can be bought in relatively large quantities.

15 Jul 2014

Efficacy News and Research

Combination drug therapy cures chronic hepatitis C in co-infected HIV patients

13 researchers awarded National Psoriasis Foundation fellowship to study psoriasis

FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

Gene therapy offers potential alternative to pacemakers

Ruthigen treats first human subjects with leading drug candidate RUT58-60

PharmaBoardroom's "Healthcare and Life Sciences Review Poland 2014" report

Phase 2 dose-ranging study of AYX1 for prevention of post-surgical pain

MPP announces 7 new sub-licensing agreements for manufacture of generic HIV medicines

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

Once-a-day pill for patients experiencing opioid-induced constipation

Phase III research shows that new drug improves symptoms related to plaque psoriasis

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

GrowBLOX enters Florida Medical Marijuana Market through new subsidiary, GB Sciences

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

Citalopram can increase efficacy of BMSCs differentiating into neuronal-like cells

OSU creates new assay to test authenticity of primary drugs used to treat malaria

Hydroxychloroquine treatment not effective for primary Sjögren syndrome

Healthy lifestyle helps hard-to-treat hypertensive patients

Pfizer to in-license Absorption Systems' BCRP-MDCK cells

Paracetamol safety and osteoarthritis: an interview with Professor David Hunter, University of Sydney

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News